Cytodyn Inc - CYDY stock

From OTC Wiki


Within the healthcare sector, CytoDyn (OTC: CYDY) is a biotechnology company that aims to unleash the unexplored realms of science and technology combined. With its headquarter in Vancouver, Washington, United States, it was founded in the year 2002. Previously, the company was called RexRay Corporation.

Based on Leronlimab which is a brand-new humanized monoclonal antibody that targets the CCR5 receptor, CytoDyn is a publicly listed late-stage biotechnology firm exploring new therapies for a variety of therapeutic purposes.[1]

Focused chiefly on developing treatments that are innovative and accessible by the masses, CytoDyn has proven to be a tremendous asset to the modern healthcare industry. Reputable members of the company's scientific advisory board with a range of specialties and backgrounds are present. Additionally, it boasts a capable management team.[1]

Innovative Technology[edit]

CytoDyn spreads its broad pipeline of indications in HIV, Oncology, COVID-19, Non-alcoholic steatohepatitis (NASH), and Multiple Sclerosis (MS).[2]

Monoclonal Antibodies, or MABs, are the name given to these cloned or replicated antibodies. A vaccination, as opposed to MABs, tries to stimulate or strengthen one's immune system to produce antibodies that are efficient in combating the foreign antigen. MAB is an inorganic strategy, whereas vaccination is an organic one.[2]

A special humanized monoclonal antibody is leronlimab. Preclinical research has also demonstrated that leronlimab suppresses calcium channel signaling of the CCR5 receptor when present on the surface of cancer cells, preventing HIV from exploiting the CCR5 receptor as an entrance gateway for healthy cells. It is thought that a key factor in the development of metastatic cancer is the calcium channel signaling of the CCR5 receptor.[2]

Not only in HIV and Cancer, but the Leronlimab has also proved effective in COVID-19 treatment. The Covid-19 individuals experience significant breathing difficulties and, in some cases, fatal outcomes as a result of the lungs becoming severely inflamed and losing their ability to function normally. Leronlimab acts to lessen this influx of immune molecules into the damaged region, which results in reduced lung inflammation and injury.[3]

Monoclonal Antibodies[edit]

Letronlimab (PRO 140), a monoclonal antibody from CytoDyn, is an experimental humanized IgG4 mAb that inhibits CCR5, a cellular receptor with potential implications for HIV infection, tumor metastasis, and immunological signaling. Nine Phase 1/2/3 clinical studies with more than 800 patients have been completed with leronlimab (PRO 140), including a major Phase 3 trial in conjunction with conventional anti-retroviral medicines in HIV-infected patients with prior treatment experience.[4]


On 10/25/21 the company announced that its first patient in Brazil has begun treatment with leronlimab for COVID -19 in its Phase 3 trial (CD16). They had previously announced the first patient in another Phase 3 trial in Brazil (CD17) on 9/9/21. According to the release, "This new pivotal Phase 3 clinical trial (CD16) will focus on hospitalized critically ill COVID-19 patients who require mechanical and invasive ventilation or Extracorporeal Membrane Oxygenation (ECMO)."[5]

Activist Group[edit]

Paul Rosenbaum, CEO and chairman of specialty chemical business SWR Corporation organized a group of 28 shareholders which subsequently nominated 5 directors for election to the company’s board. on June 30, 2021. The activist shareholders believe that the current board has done a poor job managing leronlimab.[6]

  1. 1.0 1.1 CNBC. Large shareholder group calls for a board overhaul at pharma company CytoDyn. July 24, 2021.
  2. 2.0 2.1 2.2 Pipeline. Accessed on 12/1/2022.
  3. Pipeline - COVID-19. Accessed on 12/20/2022.
  4. CytoDyn. Our Science. Accessed on 12/18/2022.
  5. Cytodyn Announces Treatment...
  6. June 30, 2021. Shareholder Group Calls for Board Overhaul

OTC Market: CYDY • Industry: Biotech | Healthcare

The page is authored by: Caesar